A November 20 report says draft letters from lawmakers in both parties and chambers are pressing Treasury in opposite directions on its proposed restrictions on U.S. investment in Chinese biotechnology.
Some lawmakers, including House China Select Committee chair John Moolenaar, want biotechnology covered more broadly or quickly, arguing U.S. investment and expertise could strengthen China’s strategic and military capabilities.
Other lawmakers are urging caution about the proposal’s scope and potential effects on U.S. biotech companies, research, and investment. The dispute reflects a broader tension between national-security concerns and preserving commercial and scientific collaboration.
Treasury’s biotechnology restrictions are still proposed, not final. They would add biotech to the outbound-investment rules under the COINS Act, with certain transactions involving China prohibited; the proposal’s comment deadline is December 7, 2026.
Sources:
More lawmakers stake out stances on China biotech investment
Implementing COINS: Treasury Proposes Restricting Outbound Investment on Biotechnology
Outbound And Down: Biotech Joins Semiconductors, Quantum And AI ...
NSCEB Statement on New Outbound Investment Rule that Includes ...
Regulation of US Outbound Investment to China
Outbound Investment Security Program
U.S. Treasury Department and China’s MOFCOM Propose ...
February 26, 2026 The Honorable Scott Bessent Secretary of the ...
RA Capital opens Shanghai office to tap Chinese biotech even as US investment rules tighten
How Three US Regimes Now Restrict Biotech Dealings With China
US panel warns of China's biotech rise, fuelling push to curb ties as Chinese firms unfazed
Treasury Draft Regulations Would Prohibit Certain U.S. Investments in ...